Autosomal dominant multiple pterygium syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:65743OMIM:178110Q79.8
Who is this for?
Show terms as
27Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Autosomal dominant multiple pterygium syndrome (also called dominant multiple pterygium syndrome or Escobar syndrome variant in some older literature) is a rare condition present from birth that mainly affects the joints and skin. The word 'pterygium' means 'wing-like web,' and in this condition, thick bands or webs of skin form across joints — most often the neck, elbows, knees, and fingers. These webs can limit how far a joint can bend or straighten, which affects movement and daily activities. Beyond the skin webs, people with this condition may have other features including a short neck, drooping eyelids, low-set ears, a small jaw, and spine problems such as scoliosis. Some individuals have differences in how their fingers or toes are formed. The severity varies quite a bit from person to person, even within the same family. Treatment focuses on managing symptoms rather than curing the condition. Surgery can sometimes release the skin webs to improve joint movement. Physical therapy and occupational therapy help people maintain strength and function. A team of specialists — including orthopedic surgeons, geneticists, and physical therapists — typically works together to support each person's needs throughout their life.

Also known as:

Key symptoms:

Skin webs or bands across joints (especially neck, elbows, knees, and fingers)Limited joint movement due to webbingShort or webbed neckDrooping eyelids (ptosis)Low-set or abnormally shaped earsSmall or receding jaw (micrognathia)Curved spine (scoliosis)Short statureWebbed fingers or toes (syndactyly)Rocker-bottom feet or other foot differencesWidely spaced nipplesUndescended testicles in males

Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events
Mar 2026Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease

University Hospital, Rouen — PHASE2

TrialNOT YET RECRUITING
Jan 2026A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Merck Sharp & Dohme LLC — PHASE3

TrialRECRUITING
Dec 2025KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Merck Sharp & Dohme LLC — PHASE2

TrialRECRUITING
Dec 2025STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

University of Cologne — PHASE3

TrialRECRUITING
Dec 2025Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease

Invicro — EARLY_PHASE1

TrialRECRUITING
Nov 2025A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

AstraZeneca — PHASE1

TrialRECRUITING
Sep 2025Resistance Training Added to Aerobic Interval Training to Improve Aerobic Capacity and Muscle Mass in Women With Coronary Artery Disease

University Medical Centre Ljubljana — NA

TrialRECRUITING
Aug 2025A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

BioNTech SE — PHASE1, PHASE2

TrialRECRUITING
Jun 2025A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Merck Sharp & Dohme LLC — PHASE3

TrialRECRUITING
May 2025A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

Merck Sharp & Dohme LLC — PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Autosomal dominant multiple pterygium syndrome.

View clinical trials →

No actively recruiting trials found for Autosomal dominant multiple pterygium syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Autosomal dominant multiple pterygium syndrome community →

Specialists

Showing 25 of 27View all specialists →
AM
Arun Rajan, M.D.
BETHESDA, MD
Specialist
PI on 11 active trials
BP
BioNTech Responsible Person
Specialist
PI on 18 active trials
OM
Ozlem Goker-Alpan, MD
Fairfax, Virginia
Specialist

Rare Disease Specialist

PI on 9 active trials
LM
Lisa Guay-Woodford, MD
WASHINGTON, DC
Specialist
PI on 2 active trials
FP
Frank Czerwiec, M.D., Ph.D.
ROCKVILLE, MD
Specialist
PI on 2 active trials
MM
Manish Sinha, PhD, MRCP (UK), MRCPCH
SPOKANE, WA
Specialist
PI on 1 active trial
KP
Katarina Stingl, Prof
BALTIMORE, MD
Specialist
PI on 1 active trial
MP
Maria V Irazabal, M.D., Ph.D.
Specialist
PI on 2 active trials
BP
Borut Jug, MD, Ph.D.
Specialist
PI on 2 active trials
SM
Sophie J. Bakri, M.D.
ROCHESTER, MN
Specialist
PI on 1 active trial
KM
Kristen Nowak, Ph.D., MPH
Specialist
PI on 1 active trial
RM
Raymond Iezzi, M.D.
ROCHESTER, MN
Specialist
PI on 1 active trial
RM
Randall J Bateman, MD
SAINT LOUIS, MO
Specialist
PI on 6 active trials
MP
May Faraj, PDt, PhD
Specialist
PI on 1 active trial
GM
Galip Can Uyar, MD
Specialist
PI on 3 active trials1 Autosomal dominant multiple pterygium syndrome publication
CM
Connie Marras, MD
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Autosomal dominant multiple pterygium syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Autosomal dominant multiple pterygium syndromeForum →

No community posts yet. Be the first to share your experience with Autosomal dominant multiple pterygium syndrome.

Start the conversation →

Latest news about Autosomal dominant multiple pterygium syndrome

Disease timeline:

New recruiting trial: Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney Disease

A new clinical trial is recruiting patients for Autosomal dominant multiple pterygium syndrome

New recruiting trial: Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)

A new clinical trial is recruiting patients for Autosomal dominant multiple pterygium syndrome

New recruiting trial: Korean NIRS-IVUS Multicenter Registry

A new clinical trial is recruiting patients for Autosomal dominant multiple pterygium syndrome

New recruiting trial: Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease

A new clinical trial is recruiting patients for Autosomal dominant multiple pterygium syndrome

New recruiting trial: Early PKD Observational Cohort Study

A new clinical trial is recruiting patients for Autosomal dominant multiple pterygium syndrome

New recruiting trial: Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC

A new clinical trial is recruiting patients for Autosomal dominant multiple pterygium syndrome

New recruiting trial: Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

A new clinical trial is recruiting patients for Autosomal dominant multiple pterygium syndrome

New recruiting trial: Genetics in the Progression of Nephropathies

A new clinical trial is recruiting patients for Autosomal dominant multiple pterygium syndrome

New recruiting trial: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

A new clinical trial is recruiting patients for Autosomal dominant multiple pterygium syndrome

New recruiting trial: Alpha-synuclein Rt-quic and Neurologic Symptoms in Persons With idiOpathic anosMiA

A new clinical trial is recruiting patients for Autosomal dominant multiple pterygium syndrome

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Which joints are most affected in my case, and what does that mean for my movement long-term?,Should I have genetic testing, and should my family members be tested too?,Is surgery recommended for my joint webs, and what results can I realistically expect?,How often should I be monitored for spine problems like scoliosis?,What physical or occupational therapy would help me most right now?,Are there any clinical trials or research studies I could participate in?,Are there patient support groups or other families I could connect with?

Common questions about Autosomal dominant multiple pterygium syndrome

What is Autosomal dominant multiple pterygium syndrome?

Autosomal dominant multiple pterygium syndrome (also called dominant multiple pterygium syndrome or Escobar syndrome variant in some older literature) is a rare condition present from birth that mainly affects the joints and skin. The word 'pterygium' means 'wing-like web,' and in this condition, thick bands or webs of skin form across joints — most often the neck, elbows, knees, and fingers. These webs can limit how far a joint can bend or straighten, which affects movement and daily activities. Beyond the skin webs, people with this condition may have other features including a short neck,

How is Autosomal dominant multiple pterygium syndrome inherited?

Autosomal dominant multiple pterygium syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Autosomal dominant multiple pterygium syndrome typically begin?

Typical onset of Autosomal dominant multiple pterygium syndrome is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Autosomal dominant multiple pterygium syndrome?

25 specialists and care centers treating Autosomal dominant multiple pterygium syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.